Intravenous treatment of idiopathic inflammatory bowel disease with anti-TNFα inhibitors (Master thesis)
The study was conducted at the Gastroenterology Clinic of the University Hospital of Ioannina and involved 61 patients collecting information on Crohn's disease and ulcerative colitis as well as on the treatment method followed.Treatment of both diseases was done by intravenous administration of Remicade every 2 months 8 weeks. The dosage of Remicade flacon was different for each patient and depends on the stage of the disease, the frequency of visits and the weight of the patient. It has been studied and evaluated the detection of disease-specific differences for all variables for all subjects, the measurement of safety with outcome index in the surgery and the detection of statistically significant factors in the association and the measurement of efficacy with outcome indicators the discontinuation of corticoids And the detection of statistically significant factors in the association of both diseases. From the study of the relationship of the variables it was observed that the frequency of administration, the rates of serious infections (1.122, sig.0.289) recorded, the proportion of patients in recession and exacerbation, the percentage of patients who discontinued corticoids, the male / female ratio (3.265, Sig.0.071) in patients, the age and years of the disease statistically and the percentage of patients being treated are the same for both diseases.
|Alternative title / Subtitle:||μελέτη ενός κέντρου αναφοράς|
study of a reference center
|Institution and School/Department of submitter:||Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής|
|Subject classification:||Έντερα -- Ασθένειες|
|Keywords:||Φλεγμονώδης νόσος του εντέρου,Ελκώδης κολίτιδα,Νόσος του Crohn,5 - Ινφλιξιμαβη,Inflammatory bowel disease(s),Ulcerative colitis,Crohn's disease,5 - Infliximab|
|Appears in Collections:||Διατριβές Μεταπτυχιακής Έρευνας (Masters)|
Please use this identifier to cite or link to this item:This item is a favorite for 0 people.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.